spacer
home > ebr > summer 2002 > technology appraisal process and presents the facts behind the nice appraisal of beta-interferon
PUBLICATIONS
European Biopharmaceutical Review

Technology Appraisal Process and presents the facts behind the NICE appraisal of beta-interferon

The National Institute for Clinical Excellence (NICE or the Institute) is part of the NHS. It provides guidance for the NHS, its patients and their carers about treatment and health care. The guidance on beta-interferon and glatiramer acetate was a part of the technology appraisals work programme. Appraisals are independent considerations of both the clinical and cost effectiveness of health technologies. Topics include medicines, medical devices, diagnostic techniques, surgical procedures and health promotion activities. The Secretary of State for Health and the Welsh Assembly Government decide which topics NICE will appraise. However, once the technology has been referred to NICE, the development of the guidance is the responsibility of NICE alone.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anne-Toni Rodgers, Communications Director of the National Institute for Clinical Excellence (NICE)

Anne-Toni Rodgers is a pharmacology graduate with a strong track record in communications with the NHS, industry and patients. Prior to joining the Institute, she spent 18 years in a variety of roles for the pharmaceutical industry including pure research, regulatory affairs, sales and marketing and government and industry affairs.
She is a graduate of the Common Purpose Programme, Vice-Chair of the London region of the Institute for Health Service Management, an editorial board member for the Journal of Quality in Healthcare and an advisory board member for the Association of Quality in Healthcare. Anne-Toni acts as an executive lead on both technology appraisals and clinical guidelines, and is a member of the management board of the National Prescribing Centre. She holds responsibility for the communication and dissemination of the Institute's work to all stakeholders. Anne-Toni joined the National Institute for Clinical Excellence on 12th July 1999.

spacer
Anne-Toni Rodgers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement